TB-500 Global Regulatory Status: FDA Approval, Legal Classification, and Access by Country

What TB-500 Actually Is (and Is Not)

TB-500 is a synthetic peptide corresponding to the 17-amino-acid active region (Ac-SDKP through the actin-binding domain) of thymosin beta-4, a 43-amino-acid protein naturally produced by the thymus and found in most human tissues. The distinction matters for regulatory purposes. Thymosin beta-4 is the endogenous full-length protein studied in clinical contexts, while TB-500 refers specifically to the truncated synthetic fragment sold commercially. No regulatory agency has approved either form for human therapeutic use.

Thymosin beta-4 was first isolated and characterized in the 1960s by Allan Goldstein at the George Washington University School of Medicine. Goldstein's 2012 review documented the protein's roles in wound healing, anti-inflammatory signaling, and tissue repair across preclinical models [1]. That foundational pharmacology generated significant interest in regenerative medicine. But preclinical promise has not yet translated into regulatory clearance anywhere in the world.

The commercial peptide market often conflates TB-500 with thymosin beta-4. They are not identical molecules. TB-500 is a fragment, typically acetylated at the N-terminus, and its pharmacokinetic profile, receptor binding affinity, and dose-response curves differ from the parent protein. No head-to-head pharmacokinetic study comparing TB-500 to full-length thymosin beta-4 has been published in a peer-reviewed journal.

United States: FDA Classification and Compounding Access

TB-500 has never received FDA approval for any indication. There is no NDA, no BLA, and no 505(b)(2) application on file for thymosin beta-4 or its fragments in the FDA's Drugs@FDA database. The molecule does not appear in the FDA's Orange Book of approved drug products.

In practice, U.S. patients access TB-500 through 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription from a licensed prescriber. This is the legal mechanism that permits TB-500 prescriptions in the United States, not FDA approval. The prescriber bears clinical responsibility for off-label or investigational use.

The FDA's position on bulk drug substances eligible for compounding remains a moving target. In 2023, the FDA published a revised framework for its bulks nominations process under the 503B pathway (outsourcing facilities), and thymosin beta-4 has been the subject of ongoing review [2]. As of May 2026, the FDA has neither explicitly added thymosin beta-4 to the approved bulks list for 503B facilities nor issued a formal prohibition.

This regulatory gray zone creates a two-tier system. Patients with access to a prescriber familiar with peptide therapies and a 503A compounding pharmacy can legally obtain TB-500. Patients without that access cannot. The peptide is not available at retail pharmacies, is not covered by any commercial insurance plan, and is not included in Medicare Part D formularies.

DEA Scheduling and Controlled Substance Status

TB-500 is not scheduled by the Drug Enforcement Administration. It does not appear on Schedules I through V of the Controlled Substances Act. This means it is not a controlled substance, and prescriptions for TB-500 do not require DEA-number documentation or tamper-resistant prescription pads in states that mandate them for scheduled drugs.

This lack of scheduling is sometimes misread as permissiveness. It is not. The absence of DEA scheduling simply means the compound has not been identified as having abuse potential warranting scheduling. The FDA still regulates it as a drug, and selling TB-500 for human consumption without a prescription violates federal law. Online vendors marketing TB-500 as a "research chemical" are operating in a regulatory gap that the FDA has addressed through warning letters to peptide sellers in multiple enforcement actions since 2019 [3].

European Medicines Agency (EMA) and EU Member States

The European Medicines Agency has not granted marketing authorization for thymosin beta-4 or TB-500 under any trade name. A search of the EMA's medicine database returns no results for either compound. No centralized marketing authorization application has been submitted.

Individual EU member states handle the compound through national pharmacy regulations. In Germany, peptides not authorized by EMA or BfArM (the German Federal Institute for Drugs and Medical Devices) can be compounded under the Arzneimittelgesetz (AMG) by licensed pharmacies on a named-patient basis. France's ANSM applies stricter limits. The UK, post-Brexit, regulates through the MHRA, which likewise has not approved thymosin beta-4.

The practical result: European patients seeking TB-500 either obtain it through compounding pharmacies in permissive jurisdictions (primarily Germany and parts of Eastern Europe) or import it from international peptide suppliers, a practice that falls into varying degrees of legal risk depending on the member state. The European Commission's Falsified Medicines Directive (2011/62/EU) applies to peptide imports and carries penalties in most member states for unauthorized importation.

Australia: TGA Regulation and the ARTG

The Australian Therapeutic Goods Administration (TGA) classifies thymosin beta-4 as a Schedule 4 (prescription-only) substance under the Poisons Standard (SUSMP). It is not, however, listed on the Australian Register of Therapeutic Goods (ARTG), which means no sponsor has submitted it for regulatory evaluation as a therapeutic product in Australia.

Australian prescribers can access unapproved therapeutic goods through the TGA's Special Access Scheme (SAS) or the Authorised Prescriber pathway. Category B of the SAS requires TGA notification and clinical justification on a per-patient basis. This pathway has been used for various peptides, though the TGA does not publish aggregated SAS approval statistics by compound name. The process is slow. Prescribers report 4 to 8 week turnaround times for SAS-B approvals.

In 2024, the TGA increased enforcement against online peptide retailers selling directly to Australian consumers. Multiple seizure notices were issued for shipments containing TB-500, BPC-157, and other synthetic peptides imported without TGA authorization [4].

WADA Prohibition and Athletic Drug Testing

The World Anti-Doping Agency added thymosin beta-4 to its Prohibited List in 2011 under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). The prohibition applies both in-competition and out-of-competition. TB-500, as a fragment of thymosin beta-4, falls under the same prohibition.

WADA's 2026 Prohibited List, published in September 2025, continues to list "thymosin-β4 and its derivatives, e.g., TB-500" as prohibited substances [5]. Testing laboratories accredited by WADA can detect thymosin beta-4 fragments in urine and blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Detection windows vary, but published analytical methods report sensitivity down to the low ng/mL range in serum.

Multiple athletes have received sanctions for thymosin beta-4 positives. The penalty is serious. A 2017 case adjudicated by the Court of Arbitration for Sport (CAS) resulted in a four-year ban for a cyclist who tested positive for thymosin beta-4 metabolites. Any athlete subject to WADA-code testing should treat TB-500 as a career-ending risk.

Dr. Olivier Rabin, Senior Executive Director of Sciences and International Partnerships at WADA, stated in a 2022 briefing: "Thymosin beta-4 and its synthetic fragments, including TB-500, are prohibited because of their potential to enhance recovery and tissue repair beyond normal physiological capacity."

Clinical Trial Status: Why Approval Remains Distant

No Phase III clinical trial for thymosin beta-4 or TB-500 has been completed as of May 2026. A search of ClinicalTrials.gov for "thymosin beta-4" returns a small number of entries, most of which are Phase I/II studies focused on corneal wound healing (conducted by RegeneRx Biopharmaceuticals) and cardiac repair following myocardial infarction.

RegeneRx's ophthalmic formulation, RGN-259, completed a Phase III trial for dry eye (NCT02974907) but the company has not filed an NDA. The systemic injectable form (RGN-352) for cardiac indications completed Phase I safety studies, and a 2012 publication reported no serious adverse events in a small cohort (N=6) receiving intravenous thymosin beta-4 at doses up to 1 to 260 mg over 14 days [6]. That trial established basic safety signals but was far too small to support regulatory filing.

The gap between preclinical evidence and clinical development is wide. Goldstein et al. (2012) catalogued over 200 preclinical publications demonstrating thymosin beta-4's activity in wound healing, cardiac repair, neurological recovery, and anti-inflammatory pathways [1]. Yet fewer than 50 human subjects have received thymosin beta-4 in registered clinical trials. Without adequately powered Phase III data, no regulatory agency can approve the compound.

The economics of peptide drug development partially explain this gap. Thymosin beta-4 is a naturally occurring protein, making patent protection difficult. RegeneRx holds composition-of-matter patents on specific formulations, but the active molecule itself is not patentable. This limits the commercial incentive for the hundred-million-dollar investment a full NDA or BLA filing requires.

Country-by-Country Quick Reference

Regulatory status varies by jurisdiction. Here is a condensed reference for the most commonly asked-about countries.

United States: Not FDA-approved. Available via 503A compounding with prescription. Not DEA-scheduled. Online "research chemical" sales are legally ambiguous.

Canada: Not approved by Health Canada. No Drug Identification Number (DIN) assigned. Access through Special Access Programme (SAP) is theoretically possible but rarely pursued for peptides of this class.

United Kingdom: Not MHRA-approved. No marketing authorization. Compounding pharmacies may prepare on a named-patient basis under the supervision of a prescriber, per the Human Medicines Regulations 2012.

Germany: Not BfArM-approved. Compounding permitted under AMG provisions. Likely the most accessible EU jurisdiction for TB-500 compounding.

Australia: Schedule 4 (prescription-only). Not on the ARTG. Accessible via TGA Special Access Scheme with clinical justification. Enforcement against unauthorized imports increasing.

Japan: Not approved by PMDA. Thymosin beta-4 products are not listed in the Japanese Pharmacopoeia. Import for personal use may be subject to Pharmaceutical Affairs Law restrictions.

China: Thymosin products (primarily thymalfasin/thymosin alpha-1, marketed as Zadaxin) have a regulatory history in China, but thymosin beta-4 and TB-500 are not NMPA-approved for any indication.

Safety Signals in the Absence of Formal Labeling

Because TB-500 has no FDA-approved label, there is no official prescribing information, black box warnings, or FDA-mandated patient medication guide. The safety profile relies entirely on preclinical data, small Phase I trials, and clinician-reported experience from compounding use.

The published human safety data, while limited, has not identified serious adverse events. The RegeneRx Phase I cardiac study (N=6) at supraphysiologic doses reported injection site reactions and transient headaches as the most common complaints [6]. The ophthalmic trials for RGN-259 showed a safety profile comparable to placebo in dry eye patients.

Theoretical concerns exist around oncogenesis. Thymosin beta-4 is overexpressed in several tumor types, and preclinical data has shown it may promote angiogenesis and cell migration in certain cancer models [1]. The National Cancer Institute's PDQ database does not list thymosin beta-4 as a known carcinogen, and no epidemiological data links exogenous TB-500 use to cancer incidence. But the absence of evidence is not evidence of absence, particularly given the small number of human subjects studied. Prescribers should exercise caution in patients with active malignancy or a strong family history of angiogenesis-dependent cancers.

Dr. Allan Goldstein, Professor Emeritus at George Washington University, noted in his 2012 review: "While the preclinical data for thymosin beta-4 in tissue repair is compelling, the transition to clinical application requires rigorous Phase II and III evaluation that has not yet occurred for systemic indications" [1].

Other reported concerns from clinical use include mild fluid retention, transient hypotension at higher doses, and localized erythema at subcutaneous injection sites. No deaths or organ-specific toxicities have been attributed to TB-500 in published literature through May 2026.

What This Means for Prescribers and Patients

Prescribers considering TB-500 for a patient should document the clinical rationale, obtain informed consent that specifically addresses the compound's unapproved status, and source exclusively from a licensed 503A pharmacy that provides a Certificate of Analysis (COA) with third-party purity testing. Patients purchasing TB-500 from unregulated online vendors face unknown risks from impurities, incorrect dosing, and potential contamination with bacterial endotoxins. A 2020 analysis of commercially available peptides purchased online found that 27% of tested samples contained less than 90% of the labeled peptide content, and 12% contained detectable microbial contamination [7].

Athletes subject to WADA, USADA, NCAA, or equivalent anti-doping codes must not use TB-500 under any circumstances. The four-year standard sanction for a first offense makes this a non-negotiable contraindication for competitive athletes.

Patients in Australia should work with a prescriber willing to file a TGA SAS-B application. Patients in EU countries should seek a prescriber familiar with their national compounding regulations. In all jurisdictions, a prescription from a licensed medical professional remains the only legally defensible access route for TB-500 intended for human use.